Download - Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES
![Page 1: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/1.jpg)
Patrick Patrick An Introduction to Medicinal An Introduction to Medicinal
ChemistryChemistry 3/e 3/e
Chapter 4Chapter 4
PROTEINS AS DRUG PROTEINS AS DRUG TARGETS:TARGETS:ENZYMESENZYMES
![Page 2: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/2.jpg)
ContentsContents
1. Structure and function of enzymes (3 slides)2. The active site3. Substrate binding
3.1. Induced fit3.2. Bonding forces (5 slides)
4. Catalysis mechanisms4.1. Acid/base catalysis4.2. Nucleophilic residues
5. Overall process of enzyme catalysis6. Competitive (reversible) inhibitors7. Non competitive (irreversible) inhibitors8. Non competitive (reversible) allosteric inhibitors (2 slides)
[18 slides]
![Page 3: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/3.jpg)
1. Structure and function of enzymes1. Structure and function of enzymes
• Globular proteins acting as the body’s Globular proteins acting as the body’s catalystscatalysts
• Speed up time for reaction to reach Speed up time for reaction to reach equilibriumequilibrium
• Lower the activation energy of a reaction by Lower the activation energy of a reaction by stabilizing the transition statestabilizing the transition stateExample:Example:
LDH = Lactate dehydrogenase (enzyme)NADH2 = Nicotinamide adenosine dinucleotide (reducing agent & cofactor)Pyruvic acid = Substrate
LDH
Pyruvic acid Lactic acid
H3CC
CO
O HO
C OCH3C
H
NADH2 NAD+++
OH OH
![Page 4: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/4.jpg)
Lowering the activation energy of reactionLowering the activation energy of reaction
Act. energy
Transition state
WITHOUT ENZYME
Product
Startingmaterial
Energy
WITH ENZYME
Product
Startingmaterial
Energy
∆G
Newtransition
state
∆G
Act. energy
• Enzymes lower the activation energy of a reaction but Enzymes lower the activation energy of a reaction but G G remains the same.remains the same.
1. Structure and function of enzymes1. Structure and function of enzymes
![Page 5: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/5.jpg)
Methods of enzyme catalysisMethods of enzyme catalysis
• Provide a reaction surface (the active site)Provide a reaction surface (the active site)
• Provide a suitable environment (hydrophobic)Provide a suitable environment (hydrophobic)
• Bring reactants togetherBring reactants together
• Position reactants correctly for reactionPosition reactants correctly for reaction
• Weaken bonds in the reactantsWeaken bonds in the reactants
• Provide acid / base catalysisProvide acid / base catalysis
• Provide nucleophilesProvide nucleophiles
1. Structure and function of enzymes1. Structure and function of enzymes
![Page 6: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/6.jpg)
2. The active site2. The active site
• Hydrophobic hollow or cleft on the enzyme surfaceHydrophobic hollow or cleft on the enzyme surface
• Accepts reactants (substrates and cofactors)Accepts reactants (substrates and cofactors)
• Contains amino acids whichContains amino acids which - bind reactants (substrates and cofactors)- bind reactants (substrates and cofactors) - catalyse the reaction- catalyse the reaction
ENZYME
Active siteActive site
![Page 7: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/7.jpg)
3. Substrate binding3. Substrate binding
• Active site is nearly the correct shape for the substrateActive site is nearly the correct shape for the substrate• Binding alters the shape of the enzyme (induced fit)Binding alters the shape of the enzyme (induced fit)• Binding will strain bonds in the substrateBinding will strain bonds in the substrate• Binding involves intermolecular bonds between functional Binding involves intermolecular bonds between functional
groups in the substrate and functional groups in the active sitegroups in the substrate and functional groups in the active site
3.1 Induced fit3.1 Induced fit
Induced fitInduced fit
SubstrateSubstrateSS
![Page 8: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/8.jpg)
• IonicIonic• H-bondingH-bonding• van der Waalsvan der Waals
3.2 Bonding forces3.2 Bonding forces
Example:Example:
SS
Enzyme
Active site
vdwvdwinteractioninteraction
ionicionicbondbond
H-bondH-bond
PheSer
OH
Asp
CO2
3. Substrate binding3. Substrate binding
![Page 9: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/9.jpg)
van der WaalsH-Bond
Ionic
H3CC
C
O
O
O
• IonicIonic• H-bondingH-bonding• van der Waalsvan der Waals
3.2 Bonding forces3.2 Bonding forces
Example:Example: Binding of pyruvic acid in LDH Binding of pyruvic acid in LDH
O
H
H3N
H-Bond
Ionicbond
Possible interactions vdw-interactions
H3CC
C
O
O
O
3. Substrate binding3. Substrate binding
![Page 10: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/10.jpg)
• Induced fit - Active site alters shape to maximise Induced fit - Active site alters shape to maximise intermolecular bondingintermolecular bonding
3.2 Bonding forces3.2 Bonding forces
Intermolecular bonds not optimum length for maximum bonding
Intermolecular bond lengths optimisedSusceptible bonds in substrate strainedSusceptible bonds in substrate more easily broken
SS Phe
SerO
H
Asp
CO2 Induced fit
SSPhe
Ser
OH
Asp
CO2
3. Substrate binding3. Substrate binding
![Page 11: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/11.jpg)
Example:Example: Binding of pyruvic acid in LDH Binding of pyruvic acid in LDH
O
H
H3N
H3CC
C
O
O
O
O
O
O
3. Substrate binding3. Substrate binding
![Page 12: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/12.jpg)
Example:Example: Binding of pyruvic acid in LDH Binding of pyruvic acid in LDH
O
H
H3N
pi bondpi bondweakenedweakened
H3CC
C
O
O
O
3. Substrate binding3. Substrate binding
![Page 13: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/13.jpg)
4. Catalysis mechanisms4. Catalysis mechanisms
• HistidineHistidine
4.1 Acid/base catalysis4.1 Acid/base catalysis
4.2 Nucleophilic residues4.2 Nucleophilic residues
NNH
+H
-H NNH
H
Non-ionisedNon-ionisedActs as a basic catalystActs as a basic catalyst(proton 'sink')(proton 'sink')
IonisedIonisedActs as an acid catalystActs as an acid catalyst(proton source)(proton source)
H3N CO2
OH
H
L-SerineL-Serine
H3N CO2
SH
H
L-CysteineL-Cysteine
![Page 14: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/14.jpg)
OH
Ser
X
Substrate
O
Ser
H2O
OH
Ser
HO Product
Serine acting as a nucleophileSerine acting as a nucleophile
4. Catalysis mechanisms4. Catalysis mechanisms
![Page 15: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/15.jpg)
5. Overall process of enzyme catalysis5. Overall process of enzyme catalysis
SS
EE
ES
PP
EE
EP
PP
EE
E + P
EE
SS
E + S
EE
• Binding interactions must be;Binding interactions must be; - strong enough to hold the substrate sufficiently long for the - strong enough to hold the substrate sufficiently long for the
reaction to occurreaction to occur - weak enough to allow the product to depart - weak enough to allow the product to depart • Implies a fine balanceImplies a fine balance• Drug design - designing molecules with stronger binding Drug design - designing molecules with stronger binding
interactions results in enzyme inhibitors which block the active interactions results in enzyme inhibitors which block the active sitesite
![Page 16: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/16.jpg)
6. Competitive (reversible) inhibitors6. Competitive (reversible) inhibitors
• Inhibitor binds reversibly to the active site Inhibitor binds reversibly to the active site • Intermolecular bonds are involved in bindingIntermolecular bonds are involved in binding• No reaction takes place on the inhibitorNo reaction takes place on the inhibitor• Inhibition depends on the strength of inhibitor binding and Inhibition depends on the strength of inhibitor binding and
inhibitor concentrationinhibitor concentration• Substrate is blocked from the active site Substrate is blocked from the active site • Increasing substrate concentration reverses inhibitionIncreasing substrate concentration reverses inhibition• Inhibitor likely to be similar in structure to the substrateInhibitor likely to be similar in structure to the substrate
II
EEEE
SS
II
EE
![Page 17: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/17.jpg)
7. Non competitive (irreversible) inhibitors7. Non competitive (irreversible) inhibitors
• Inhibitor binds irreversibly to the active site Inhibitor binds irreversibly to the active site • Covalent bond formed between the drug and the enzymeCovalent bond formed between the drug and the enzyme• Substrate is blocked from the active site Substrate is blocked from the active site • Increasing substrate concentration does not reverse inhibitionIncreasing substrate concentration does not reverse inhibition• Inhibitor likely to be similar in structure to the substrateInhibitor likely to be similar in structure to the substrate
X
OH OH
X
O
Covalent Bond
Irreversible inhibition
![Page 18: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/18.jpg)
ACTIVE SITE (open)
ENZYMEEnzyme
8. Non competitive (reversible) allosteric inhibitors8. Non competitive (reversible) allosteric inhibitors
• Inhibitor binds reversibly to the allosteric site Inhibitor binds reversibly to the allosteric site • Intermolecular bonds are formedIntermolecular bonds are formed• Induced fit alters the shape of the enzymeInduced fit alters the shape of the enzyme• Active site is distorted and is not recognised by the substrateActive site is distorted and is not recognised by the substrate• Increasing substrate concentration does not reverse inhibitionIncreasing substrate concentration does not reverse inhibition• Inhibitor is not similar in structure to the substrateInhibitor is not similar in structure to the substrate
AllostericAllostericsitesite
Active siteActive site
(open)ENZYMEEnzyme
Inducedfit
Active siteActive siteunrecognisableunrecognisable
Allostericinhibitor
![Page 19: Patrick An Introduction to Medicinal Chemistry 3/e Chapter 4 PROTEINS AS DRUG TARGETS: ENZYMES](https://reader035.vdocuments.mx/reader035/viewer/2022070401/56649f1e5503460f94c35351/html5/thumbnails/19.jpg)
8. Non competitive (reversible) allosteric inhibitors8. Non competitive (reversible) allosteric inhibitors
• Enzymes with allosteric sites often at start of biosynthetic Enzymes with allosteric sites often at start of biosynthetic pathwayspathways
• Enzyme is controlled by the final product of the pathwayEnzyme is controlled by the final product of the pathway• Final product binds to the allosteric site and switches off Final product binds to the allosteric site and switches off
enzymeenzyme• Inhibitor may have a similar structure to the final productInhibitor may have a similar structure to the final product
P’’’P’’P’
Biosynthetic pathway
Feedback controlInhibition
PPSS
(open)ENZYMEEnzyme